Alternative splice variants of DCLK1 mark cancer stem cells, promote self‐renewal and drug‐resistance, and can be targeted to inhibit tumorigenesis in kidney cancer

International Journal of Cancer, EarlyView.


from Cancer via ola Kala on Inoreader https://ift.tt/2EQSOyH
via IFTTT